CAPTOPRIL

**Class:** Angiotensin-Converting Enzyme (ACE) Inhibitor

**Indications:** Management of hypertension; treatment of heart failure, left ventricular dysfunction after myocardial infarction, diabetic nephropathy

**Unlabeled:** To delay the progression of nephropathy and reduce risks of cardiovascular events in hypertensive patients with type 1 or 2 diabetes mellitus; treatment of hypertensive crisis, rheumatoid arthritis; diagnosis of anatomic renal artery stenosis, hypertension secondary to scleroderma renal crisis; diagnosis of aldosteronism, idiopathic edema, Bartter's syndrome, postmyocardial infarction for prevention of ventricular failure; increase circulation in Raynaud's phenomenon, hypertension secondary to Takayasu's disease

**Dosage:** **Note:** Titrate dose according to patient's response; use lowest effective dose.

**Acute hypertension (urgency/emergency):** Oral: 12.5-25 mg, may repeat as needed (may be given sublingually, but no therapeutic advantage demonstrated)

**Heart failure:** initial dose: 6.25-12.5 mg 3 times/day. Target dose: 50 mg 3times/day

**Hypertension:** Oral: Initial dose: 25 mg 2-3 times/day, may increase by 12.5-25 mg/dose at 1- to 2-week intervals up to 50 mg 3 times/day.

**LV dysfunction following MI:** Oral: Initial: 6.25 mg; if tolerated, follow with 12.5 mg 3 times/day; then increase to 25 mg 3 times/day during next several days and then gradually increase over next several weeks to target dose of 50 mg 3 times/day

**Diabetic nephropathy:** Oral: Initial: 25 mg 3 times/day. May be taken with other antihypertensive therapy if required to further lower blood pressure.

**Dosing: Renal Impairment:**
- **Cl**\(_{cr}\) 10-50 mL/minute: Administer at 75% of normal dose every 12-18 hours.
- **Cl**\(_{cr}\)<10 mL/minute: Administer at 50% of normal dose every 24 hours.

Intermittent hemodialysis (IHD): Administer after hemodialysis on dialysis days

Peritoneal dialysis: Dose for **Cl**\(_{cr}\) 10-50 mL/minute; supplemental dose is not necessary
**Dosing: Hepatic Impairment** No dosage adjustment provided in manufacturer’s labeling.

**Available dosage form in the hospital:** 25MG TAB, 50MG TAB

**Common side effect:** Cardiovascular: Angioedema, cardiac arrest, cerebrovascular insufficiency, rhythm disturbances, orthostatic hypotension, syncope, flushing, pallor, angina, MI, Raynaud's syndrome, CHF

Central nervous system: Ataxia, confusion, depression, nervousness, somnolence

Hematologic: Anemia, thrombocytopenia, pancytopenia, agranulocytosis, anemia

Hepatic: Jaundice, hepatitis, hepatic necrosis (rare), cholestasis, hyponatremia (symptomatic), transaminases increased

Renal: Renal insufficiency, renal failure, nephrotic syndrome, polyuria, oliguria

**Pregnancy Risk Factor:** D